ISIS Volume Alert - ISIS 51.85 Isis Pharmaceuticals $ISIS Hit a high of 51.93 Currently 11:15 Last price 51.85 +4.62 +9.78% With a day low of 48.10 and a current volume of 3,216,436.
ISIS Isis Pharmaceuticals Recent Headline News
One Reason Isis Pharmaceuticals (ISIS) Stock Is Gaining Today
at The Street - 1 hr 15 mins ago
Isis Pharmaceuticals (ISIS) stock is up after the company announced it will offer $425 million in convertible senior notes.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals to launch USD425m convertible senior notes in private placement
M2 - Tue Nov 11, 6:57AM CST
Antisense drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Monday that it plans to offer USD425.0m aggregate principal amount of convertible senior notes due 2021 in a private placement.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
PR Newswire - Mon Nov 10, 3:03PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement. Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $63.75 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any.
ISIS: 51.27 (+4.04)
ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:52PM CST
ISIS: 51.27 (+4.04)
34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 51.27 (+4.04)
Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 326.90 (-0.97), ALNY: 100.48 (+1.30), ISIS: 51.27 (+4.04), OGXI: 2.16 (+0.03), TEVA: 58.57 (+0.53), RGLS: 20.34 (-0.57), GSK: 45.78 (+0.62), SNY: 46.77 (+0.58)
Isis ups revenues 87% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:53AM CST
ISIS: 51.27 (+4.04)
Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:33AM CST
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 326.90 (-0.97), ISIS: 51.27 (+4.04)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST
BAM: 49.55 (-0.76), ERF: 15.05 (+0.64), LXP: 10.99 (-0.04), PGEM: 13.09 (+0.07), CCOI: 34.15 (+0.88), TTI: 8.60 (+0.02), SJI: 58.22 (+0.24), NXST: 44.97 (+0.45), VSAT: 62.99 (-0.02), MT: 12.15 (-0.10), LXU: 31.01 (-0.48), HUM: 134.53 (+2.07), PGNX: 6.48 (+0.51), MHR: 4.51 (-0.02), CTB: 32.60 (-0.13), IDRA: 2.60 (+0.07), ISIS: 51.27 (+4.04), BPL: 77.37 (-1.25), SSP: 18.45 (-0.11), AGIO: 84.09 (+2.31), EBIX: 16.41 (+0.81)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.27 (+4.04), SNY: 46.77 (+0.58)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 326.90 (-0.97), ISIS: 51.27 (+4.04)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 93.36 (+0.13), BDSI: 16.32 (+0.12), ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 8:15AM CST
ISIS data by YCharts What: Shares of ISIS Pharmaceuticals , a biopharmaceutical company using its proprietary antisense technology platform to develop therapies across a wide range of diseases, catapulted higher by 19% in October, based on...
ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
PR Newswire - Wed Nov 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers. Isis will earn the second $7.5 million milestone payment from AstraZeneca upon initiation of a Phase 2 study. Isis has completed a clinical study of ISIS-STAT3Rx in patients with advanced cancers and plans to present results from this study at an upcoming medical meeting. AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 clinical study in patients with advanced metastatic liver cancer. AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.
ISIS: 51.27 (+4.04)
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Nov 03, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17.00 per share. Of the total 6,088,235 shares sold in the offering, 4,808,824 shares were sold by Regulus and 1,279,411 shares were sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (NASDAQ:ISIS). The net proceeds to Regulus from the offering are expected to be approximately $76.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of shares by Isis.
ISIS: 51.27 (+4.04), DB: 30.05 (+0.05), RGLS: 20.34 (-0.57)
Isis earns milestone payment from GSK
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:09AM CST
ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
ISIS Isis Pharmaceuticals Recent Headline News
One Reason Isis Pharmaceuticals (ISIS) Stock Is Gaining Today
at The Street - 1 hr 15 mins ago
Isis Pharmaceuticals (ISIS) stock is up after the company announced it will offer $425 million in convertible senior notes.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals to launch USD425m convertible senior notes in private placement
M2 - Tue Nov 11, 6:57AM CST
Antisense drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Monday that it plans to offer USD425.0m aggregate principal amount of convertible senior notes due 2021 in a private placement.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
PR Newswire - Mon Nov 10, 3:03PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement. Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $63.75 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. ISIS: 51.27 (+4.04)
ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:52PM CST
ISIS: 51.27 (+4.04)
34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 51.27 (+4.04)
Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 326.90 (-0.97), ALNY: 100.48 (+1.30), ISIS: 51.27 (+4.04), OGXI: 2.16 (+0.03), TEVA: 58.57 (+0.53), RGLS: 20.34 (-0.57), GSK: 45.78 (+0.62), SNY: 46.77 (+0.58)
Isis ups revenues 87% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:53AM CST
ISIS: 51.27 (+4.04)
Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:33AM CST
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 51.27 (+4.04)
Isis Pharmaceuticals earns USD10m milestone payment for advancement of antisense drug ISIS-BIIB3 Rx
M2 - Fri Nov 07, 6:22AM CST
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Thursday that it expects to receive USD10m milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx.
BIIB: 326.90 (-0.97), ISIS: 51.27 (+4.04)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST
BAM: 49.55 (-0.76), ERF: 15.05 (+0.64), LXP: 10.99 (-0.04), PGEM: 13.09 (+0.07), CCOI: 34.15 (+0.88), TTI: 8.60 (+0.02), SJI: 58.22 (+0.24), NXST: 44.97 (+0.45), VSAT: 62.99 (-0.02), MT: 12.15 (-0.10), LXU: 31.01 (-0.48), HUM: 134.53 (+2.07), PGNX: 6.48 (+0.51), MHR: 4.51 (-0.02), CTB: 32.60 (-0.13), IDRA: 2.60 (+0.07), ISIS: 51.27 (+4.04), BPL: 77.37 (-1.25), SSP: 18.45 (-0.11), AGIO: 84.09 (+2.31), EBIX: 16.41 (+0.81)
All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline
Brian Orelli, The Motley Fool - Motley Fool - Thu Nov 06, 2:17PM CST
Isis Pharmaceuticals releases earnings on Friday, but don't expect the company to give investors much information about the launch of its approved drug, Kynamaro. The drug is sold by Isis' marketing partner Sanofi , which doesn't break out sales...
ISIS: 51.27 (+4.04), SNY: 46.77 (+0.58)
Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
PR Newswire - Thu Nov 06, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
BIIB: 326.90 (-0.97), ISIS: 51.27 (+4.04)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 93.36 (+0.13), BDSI: 16.32 (+0.12), ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 8:15AM CST
ISIS data by YCharts What: Shares of ISIS Pharmaceuticals , a biopharmaceutical company using its proprietary antisense technology platform to develop therapies across a wide range of diseases, catapulted higher by 19% in October, based on...
ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
PR Newswire - Wed Nov 05, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers. Isis will earn the second $7.5 million milestone payment from AstraZeneca upon initiation of a Phase 2 study. Isis has completed a clinical study of ISIS-STAT3Rx in patients with advanced cancers and plans to present results from this study at an upcoming medical meeting. AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 clinical study in patients with advanced metastatic liver cancer. AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.
ISIS: 51.27 (+4.04)
Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Mon Nov 03, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17.00 per share. Of the total 6,088,235 shares sold in the offering, 4,808,824 shares were sold by Regulus and 1,279,411 shares were sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (NASDAQ:ISIS). The net proceeds to Regulus from the offering are expected to be approximately $76.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of shares by Isis.
ISIS: 51.27 (+4.04), DB: 30.05 (+0.05), RGLS: 20.34 (-0.57)
Isis earns milestone payment from GSK
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:09AM CST
ISIS: 51.27 (+4.04), GSK: 45.78 (+0.62)
